Evidence map›Paper›PMID 30768683›Full record

ArticleAnnals of human genetics2019

Regions of homozygosity as risk factors for multiple myeloma.

Molly Went, Amit Sud, Ni Li, David C Johnson, Jonathan S Mitchell, Martin Kaiser, Richard S Houlston

Open access · hybridAbstract read
In one paragraph

Article in Annals of human genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Molly WentDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID 0000-0003-3271-975X
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Ni LiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
David C JohnsonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Jonathan S MitchellDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Martin KaiserDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Institute of Cancer Research · GB

Funding

Blood Cancer UKCancer Research UK C1298/A8362Medical Research Council G1001799
6 · The paper itself

Abstract

Genomic regions of homozygosity (ROH), detectable in outbred populations, have been implicated as determinants of inherited risk. To examine whether ROH is associated with risk of multiple myeloma (MM), we performed whole-genome homozygosity analysis using single-nucleotide polymorphism genotype data from 2,282 MM cases and 5,197 controls, with replication in an additional 878 MM cases and 7,083 controls. Globally, the distribution of ROH between cases and controls was not significantly different. However, one ROH at chromosome 9q21, harboring the B-cell transcription factor gene KLF9, showed evidence of a consistent association and may therefore warrant further investigation as a candidate risk factor for MM. Overall, our analysis provides little support for a homozygosity signature being a significant factor in MM risk.

Indexed as

AllelesGenetic Association StudiesGenetic Predisposition to DiseaseHomozygoteAgedCase-Control StudiesGenome-Wide Association StudyGenotypeHumansMiddle AgedMultiple MyelomaPolymorphism, Single NucleotideRisk AssessmentRisk Factorsgeneticsmultiple myelomarisk factor

Identifiers

PMID30768683
PMCPMC6563058
OpenAlexW2911816545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.